## Melissa J Mcdonnell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5134493/publications.pdf

Version: 2024-02-01

24 papers 2,550 citations

567281 15 h-index 677142 22 g-index

24 all docs

24 docs citations

times ranked

24

1823 citing authors

#	Article	IF	CITATIONS
1	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	6.7	788
2	A Comprehensive Analysis of the Impact of <i>Pseudomonas aeruginosa </i> Colonisation on Prognosis in Adult Bronchiectasis. Annals of the American Thoracic Society, 2015, 12, 1602-11.	3.2	258
3	Etiology of Non–Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society, 2015, 12, 1764-1770.	3.2	233
4	Clinical phenotypes in adult patients with bronchiectasis. European Respiratory Journal, 2016, 47, 1113-1122.	6.7	215
5	Characterization of the "Frequent Exacerbator Phenotype―in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	5.6	215
6	Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respiratory Medicine, the, 2016, 4, 969-979.	10.7	210
7	The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	6.7	150
8	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	6.3	116
9	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent RiskÂFactor for Mortality in Patients WithÂBronchiectasis. Chest, 2017, 151, 1247-1254.	0.8	81
10	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal, 2020, 55, 2000351.	6.7	81
11	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	6.7	63
12	Characterization of bronchiectasis in the elderly. Respiratory Medicine, 2016, 119, 13-19.	2.9	28
13	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. Respiratory Medicine, 2016, 112, 51-58.	2.9	27
14	Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1133-1145.	5.6	26
15	Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. Journal of Cystic Fibrosis, 2017, 16, 124-131.	0.7	20
16	Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review. ERJ Open Research, 2020, 6, 00190-2019.	2.6	15
17	Patterns of Disease in Patients with Middle-Lobe Predominant Bronchiectasis. Respiration, 2017, 93, 406-414.	2.6	10
18	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	3.2	6

#	Article	IF	CITATIONS
19	Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Research, 2019, 5, 00225-2018.	2.6	3
20	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Research, 2020, 6, 00341-2019.	2.6	3
21	Risk factors for lung disease progression in children with cystic fibrosis. European Respiratory Journal, 2018, 52, 1801492.	6.7	1
22	Bendopnoea in exercise limited patients with COPD. Respiratory Medicine, 2019, 154, 141-143.	2.9	1
23	ERS International Congress 2021: highlights from the Respiratory Infections Assembly. ERJ Open Research, 0, , 00642-2021.	2.6	O
24	Epithelial Mesenchymal Plasticity as a Potential Common Link between Lung Disease and Increased Risk of Lung Cancer. Annals of the American Thoracic Society, 0, , .	3.2	0